Cardiovascular Systems rallies on FDA approval for Diamondback 360

|About: Cardiovascular Systems, Inc. (CSII)|By:, SA News Editor

Cardiovascular Systems (CSII +18.4%) soars after the FDA grants PMA approval for the company's Diamondback 360 Coronary Orbital Atherectomy System to treat severely calcified coronary arteries.

This is the "first new coronary atherectomy system in more than two decades," the company notes, adding that "CSI will begin a controlled commercial launch of its Diamondback 360 Coronary OAS immediately." (PR)

Here's Benchmark's Jan Wald: "We believe this is an important milestone for the company, as it allows CSII to enter the $1.5B market to treat severely calcified coronary lesions with a differentiated product."

Benchmark raises its price target to $35 from $26.